We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Weezion

Weezion SAS develops and promotes rapid and economic solutions for In-vitro Diagnosis (IVD) of bacteremia or fungemia... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Diagnostic Solution Identifies Sepsis Causing Microorganisms and Predicts Antibiotic Resistance in 90 Minutes

By LabMedica International staff writers
Posted on 06 Jun 2022
Print article
Image: The Weezion dx solution is designed for medical analysis hospital platforms that diagnose bacteremia (Photo courtesy of Weezion)
Image: The Weezion dx solution is designed for medical analysis hospital platforms that diagnose bacteremia (Photo courtesy of Weezion)

Sepsis is a life-threatening organ dysfunction caused by the body’s toxic response to infection and can progress to septic shock, which has a mortality rate of 40%. A blood culture is the main way to check for the microbial agent (bacteria or fungi) causing the infection and will allow to diagnose the bacteremia or fungemia as well as determine the sensitivity of these microorganisms to antibiotics and antifungals. The speed at which appropriate treatment can be administered, based on the type of infection, determines the survival of the patient. Now, a new in-vitro diagnostic solution for microbial infections identifies the pathogen(s) as well as allows to identify and predict the resistance profile within 90 minutes to ensure that the appropriate anti-infective treatment can be adapted or administered quickly, reducing the risk of death in severe systemic infections.

Weezion’s (Lyon, France) Weezion dx solution is based on a proteomic approach using patented targeted mass spectrometry technology and identifies the pathogen(s) present in the clinical sample, as well as jointly detects and quantifies the proteins responsible for antibiotic resistance. Using a positive blood culture, the solution allows clinicians to identify and predict the resistance profile within 90 minutes.

Despite major advances in the last 20 years in understanding the pathophysiology of sepsis, no therapeutic revolution has yet seen the light of day. It is therefore in the diagnostic phase where progress can be made. Reducing the time to receive the results of the identification of the pathogen and its resistance profile will ensure a more rapid implementation or adaptation of a suitable anti-infective treatment. Existing identification methods, based on the molecular detection of the main pathogens and some of their resistance genes, are expensive and non-exhaustive. MALDI/TOF mass spectrometry technology has shortened the identification phase but does not provide any prediction of resistance. The rapid antibiogram from a positive blood culture vial takes several hours of incubation before validation and most of the technologies used are expensive. Therefore there is an urgent need for a resistance identification and determination tool that is rapid, more comprehensive than current methods and economically sustainable.

Designed for medical analysis hospital platforms that diagnose bacteremia, the Weezion dx solution is comprised of an operational pre-analytical sample protocol from a blood culture aliquot that requires limited manual or automated steps, in less than 10 minutes. It follows a global analytical protocol that guarantees a 90-minute diagnostic phase and allows the management of three blood culture samples per hour in order to satisfy the maximum flow of large hospital microbiology platforms. It includes prototype software to manage the decision tree of the mass spectrometry and enables identification of a panel of scout ribosomal peptides specific to microbial families or species that allows for the implementation of a decision tree to ensure accurate identification of 98% of pathogens associated with bacteremia. The Weezion dx solution also enables the identification of a panel of peptides that detects the resistance mechanisms to the three main types of antibiotics used to treat bacteremia.

Related Links:
Weezion 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.